Paper Details

Skip to Main Content

Paper Title

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.

Paper Journal Title

Transl Cancer Res

Paper Citation Count

8

Paper Publication Year

2022

Bio Mention

Mesh Descriptor

Author Name	Affiliation
Mengling Liu	Zhongshan Hospital affiliated to Fudan University
Ping Liang	Zhongshan Hospital affiliated to Fudan University

1 - 2

Dataset	Description	Source Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link
PubMed	Citations and abstracts of biomedical literature	Link

1 - 15